Abstract
The emergence of SARS-CoV-2 in late December 2019 has taken the world by storm. In March 2020, the World Health Organization (WHO) named this virus COVID-19. To date, it has infected approximately 186 million people worldwide and is attributed as the cause of death of more than 5 million people (and this number is only increasing.) The global effort to develop vaccines and therapeutics occurred at the fastest pace yet, with several vaccines' approval under emergency authorization use. There are also several post-marketing side effects, including myocarditis, cerebral venous embolism, and Guillain Barre Syndrome. Global vaccine disparity complicates the control of pandemic challenges. Several highly infectious variants have emerged, and more variants are feared to emerge if global vaccination plans are not developed soon.
Highlights
The COVID-19 pandemic, which continues to infect human lives across the globe, is far from over
In the race of vaccine development to halt the rapid progression of the virus, which is causing an increase in morbidity and mortality, Phase II and III trials were run concurrently [5]
Vaccine producers like the Serum Institute of India and other significant global laboratories were contacted by vaccine developers to produce vaccines on a large scale.Several vaccines began to emerge, despite the fact that they had not yet been published in peer-reviewed journals [10]
Summary
The COVID-19 pandemic, which continues to infect human lives across the globe, is far from over. Several different technologies have been used to develop these vaccines. In the race of vaccine development to halt the rapid progression of the virus, which is causing an increase in morbidity and mortality, Phase II and III trials were run concurrently [5].
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
